Gossamer Bio, Inc.
Gossamer Bio, Inc. (GOSS): 4 pipeline candidates · 2 upcoming catalysts · ~8 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
8.1 months
D/E -1.80 · 0% dilution
Lead: Phase 3
4 candidates
2 upcoming, next in ~166d
N/A
A transparent, data-derived signal for Gossamer Bio, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$87.5M
Cash
$41.0M
Quarterly Burn
$38.7M
Runway
8.1 mo
Revenue
$17.0M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| GB002 | Phase 2 |
| rt234 | Preclinical |
| seralutinib | Phase 3 |
| seralutinib (GB002) | Phase 3 |
Upcoming Catalysts (2)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
187
Total value held
$50.1M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 18,789,186 | $6.2M |
| blackrock, inc. | 16,826,695 | $5.5M |
| aqr capital management llc | 10,126,897 | $3.3M |
| arch venture management, llc | 8,055,916 | $2.6M |
| samsara biocapital, llc | 7,222,559 | $2.4M |
| balyasny asset management l.p. | 5,922,298 | $1.9M |
| 683 capital management, llc | 5,000,000 | $1.6M |
| hhlr advisors, ltd. | 4,974,041 | $1.6M |
| geode capital management, llc | 4,939,691 | $1.6M |
| qube research & technologies ltd | 4,917,763 | $1.6M |
Showing top 10 of 187 institutional holders of Gossamer Bio, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Gossamer Bio, Inc.'s pipeline?
Gossamer Bio, Inc. (GOSS) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Gossamer Bio, Inc.'s lead drug candidate?
Gossamer Bio, Inc.'s most advanced tracked candidate is GB002 (Phase 2) for Pulmonary Arterial Hypertension.
What is Gossamer Bio, Inc.'s next catalyst?
Gossamer Bio, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: An Open-label Extension Study Evaluating the Long-term Safety and Efficacy of Seralutinib Orally Inh" — expected December 1, 2026.
What is Gossamer Bio, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Gossamer Bio, Inc. has approximately 8.1 months of cash runway.
What is Gossamer Bio, Inc.'s market capitalization?
Gossamer Bio, Inc.'s market capitalization is approximately $87.5M.
Get the full picture on Gossamer Bio, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.